Trust tied to IRADIMED (NASDAQ: IRMD) CEO sells 5,000 via 10b5-1 plan

Q: Who is the reporting person in this IRMD Form 4 filing?

The reporting person is Roger E. Susi , who serves as CEO, President, Chairman , a director , and a 10% owner of IRADIMED Corporation (IRMD) . The reported transactions involve shares held indirectly through trusts associated with him.

Q: How many IRMD shares were sold in this Form 4 and by whom?

A total of 5,000 shares of IRADIMED common stock were sold on January 5, 2026 . The sales were reported as indirect, carried out by the Phillip Susi 2008 Dynasty Trust , a trust associated with Roger E. Susi.

Q: What IRMD shareholdings remain after the reported transactions?

Following the reported sales, the Phillip Susi 2008 Dynasty Trust held 2,277,500 IRADIMED common shares. The filing also reports indirect holdings of 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust .

Q: Are the IRMD shares held directly by Roger E. Susi or through entities?

The shares in this filing are reported as held indirectly . The transactions involve the Phillip Susi 2008 Dynasty Trust , and additional holdings are reported through the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust .

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

IRADIMED Corporation insider activity centered on trust-held shares linked to its CEO. A trust associated with CEO, President and Chairman Roger E. Susi, the Phillip Susi 2008 Dynasty Trust, sold a total of 5,000 shares of IRADIMED common stock on January 5, 2026 in multiple transactions coded as open-market sales.

The reported weighted average sale prices ranged from $95.10 to $99.48, with underlying trade price ranges disclosed between $94.55 and $99.60, all under a Rule 10b5-1 trading plan adopted on June 16, 2025. After these sales, the Phillip Susi 2008 Dynasty Trust held 2,277,500 shares, while additional indirect holdings reported for Roger E. Susi were 162,950 shares through the Roger E. Susi Revocable Trust and 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust.

Insider Trade Summary

Net Seller: 5,000 shares ($488,417)

Net Sell 7 txns

Insider Susi Roger E.

Role CEO, PRESIDENT, CHAIRMAN

Sold 5,000 shs ($488K)

Type	Security	Shares	Price	Value
Sale	Common Stock	854	$95.10	$81K
Sale	Common Stock	300	$95.58	$29K
Sale	Common Stock	883	$97.52	$86K
Sale	Common Stock	2,209	$98.42	$217K
Sale	Common Stock	754	$99.48	$75K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,281,646 shares (Indirect, By Phillip Susi 2008 Dynasty Trust)

Footnotes (1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. This transaction was executed in multiple trades at prices ranging from $94.55 to $95.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $97.09 to $98.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $98.12 to $98.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $99.41 to $99.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

Form 4 Insider Transactions: What Each Field Means →

01/06/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last)

(First)

(Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO

32826

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PRESIDENT, CHAIRMAN

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/05/2026		S⁽¹⁾		854	D	$95.1⁽²⁾	2,281,646	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	01/05/2026		S⁽¹⁾		300	D	$95.58	2,281,346	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	01/05/2026		S⁽¹⁾		883	D	$97.52⁽³⁾	2,280,463	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	01/05/2026		S⁽¹⁾		2,209	D	$98.42⁽⁴⁾	2,278,254	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	01/05/2026		S⁽¹⁾		754	D	$99.48⁽⁵⁾	2,277,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500⁽⁶⁾	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

2. This transaction was executed in multiple trades at prices ranging from $94.55 to $95.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $97.09 to $98.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $98.12 to $98.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $99.41 to $99.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Roger E. Susi	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the reporting person in this IRMD Form 4 filing?

The reporting person is Roger E. Susi, who serves as CEO, President, Chairman, a director, and a 10% owner of IRADIMED Corporation (IRMD). The reported transactions involve shares held indirectly through trusts associated with him.

How many IRMD shares were sold in this Form 4 and by whom?

A total of 5,000 shares of IRADIMED common stock were sold on January 5, 2026. The sales were reported as indirect, carried out by the Phillip Susi 2008 Dynasty Trust, a trust associated with Roger E. Susi.

At what prices were the IRMD shares sold in this insider transaction?

The 5,000 shares were sold in several trades with reported weighted average prices of $95.10, $95.58, $97.52, $98.42, and $99.48. Footnotes state that individual trade prices ranged from $94.55 up to $99.60.

Was this IRMD insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. Such plans allow pre-arranged trading according to preset instructions.

What IRMD shareholdings remain after the reported transactions?

Following the reported sales, the Phillip Susi 2008 Dynasty Trust held 2,277,500 IRADIMED common shares. The filing also reports indirect holdings of 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust.

Are the IRMD shares held directly by Roger E. Susi or through entities?

The shares in this filing are reported as held indirectly. The transactions involve the Phillip Susi 2008 Dynasty Trust, and additional holdings are reported through the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust.